新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » CRO/CMO » 药明康德新一季度营收两位数增长助力全球扩张

药明康德新一季度营收两位数增长助力全球扩张

来源:生物谷 2014-05-19 09:05

2014年5月18日讯 /生物谷BIOON/ --作为中国最大的合约研究机构之一无锡药明康德公司最近公布了公司新一季度财报,数据显示公司净收入度增长了11.3%之多。上一季度公司的净收入达到1亿4千6百万美元,其中实验室服务增长8.3%,达到1亿5百万美元;加工生产业务达到4100万美元,增长了19.7%。另一方面,公司的中国国内业务增加了10.3%,美国市场业务增加1.7%。公司预计2014年公司的总收入将达到6亿6千万美元到6亿7千万美元。目前药明康德公司正努力拓展全球业务,公司2014年斥资8500万美元用于海外市场的开发,比去年增长了50%之多。公司CEO表示,药明康德目前正在努力将自己建设为一家能够为各种药物研发服务的全球性合约研究机构。(生物谷Bioon.com)

详细英文报道:

Chinese CRO WuXi PharmaTech ($WX) notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.

Net revenue came in at $146.7 million on the quarter, driven by 8.3% growth in lab services, which brought in $105.5 million, and a 19.7% leap in manufacturing, which came in at $41.2 million. WuXi's in-China CRO sales jumped 10.3% to $82.1 million, and its U.S. division grew 1.7% to $23.4 million. The company reported a $13.9 million charge related to foreign exchange rates, dragging profits down 17.9% to $17.8 million on an otherwise impressive quarter.

WuXi is keeping its 2014 projections intact, expecting full-year revenue to come in between $660 million and $670 million, good for up to 16% annual growth.

The CRO has been spending money to broaden its reach in the U.S. and China on both the clinical and manufacturing fronts. WuXi expects to spend about $85 million on capital expenditures in 2014--50% more than the year before--to keep its growth rolling, CEO Ge Li said.

"The favorable biotech funding environment in the U.S. will generate new business throughout our organization in the next few years as our integrated drug discovery and development platform enables biotech companies to utilize our capabilities and capacity to rapidly advance their product pipelines," Li said in a statement. "... The company remains focused on its mission of building the best open-access platform of services and technologies to enable anyone and any company to discover, develop, and commercialize healthcare products to benefit the world's patients."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库